Meridian Bioscience Inc. (NASDAQ:VIVO) announced a quarterly dividend on Wednesday, November 8th, NASDAQ reports. Shareholders of record on Monday, November 20th will be given a dividend of 0.125 per share on Thursday, November 30th. This represents a $0.50 annualized dividend and a yield of 3.44%. The ex-dividend date of this dividend is Friday, November 17th.

Meridian Bioscience (NASDAQ VIVO) traded down $0.25 on Friday, reaching $14.55. 126,200 shares of the company’s stock traded hands, compared to its average volume of 289,524. The company has a current ratio of 6.47, a quick ratio of 4.42 and a debt-to-equity ratio of 0.31. Meridian Bioscience has a 12 month low of $10.75 and a 12 month high of $18.58. The stock has a market capitalization of $614.05, a P/E ratio of 21.40 and a beta of 0.89.

Meridian Bioscience (NASDAQ:VIVO) last released its quarterly earnings data on Thursday, November 9th. The company reported $0.15 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.15. Meridian Bioscience had a net margin of 10.74% and a return on equity of 17.07%. The company had revenue of $49.70 million during the quarter, compared to the consensus estimate of $48.28 million. During the same period in the previous year, the firm earned $0.14 earnings per share. Meridian Bioscience’s revenue for the quarter was up 5.7% on a year-over-year basis. equities research analysts anticipate that Meridian Bioscience will post 0.66 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at

In other news, Chairman John A. Kraeutler bought 7,000 shares of the firm’s stock in a transaction dated Thursday, August 24th. The stock was acquired at an average cost of $13.67 per share, for a total transaction of $95,690.00. Following the completion of the purchase, the chairman now owns 345,230 shares of the company’s stock, valued at $4,719,294.10. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 2.30% of the stock is currently owned by corporate insiders.

Several research firms have issued reports on VIVO. BidaskClub downgraded shares of Meridian Bioscience from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 2nd. Canaccord Genuity reiterated a “hold” rating and set a $14.00 price objective on shares of Meridian Bioscience in a research note on Friday, October 13th. Finally, Zacks Investment Research upgraded shares of Meridian Bioscience from a “sell” rating to a “hold” rating in a research note on Thursday, October 5th. Three research analysts have rated the stock with a sell rating and three have given a hold rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $14.00.

Meridian Bioscience Company Profile

Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.

Dividend History for Meridian Bioscience (NASDAQ:VIVO)

Receive News & Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.